Figure 1. UMCD6 increases survival and augments killing by human PBMC of a breast cancer line xenotransplanted into immunodeficient mice.

A: Schematic representation of in vivo visualization of tumor growth by the IVIS imaging system. B: 2×10⁶ MDA-MB-231 cells were inoculated s.c. in the abdomen of female SCID/beige mice. Once tumors reached 1 cm, mice were administered 10×10⁶ human PBMCs by tail vein (day 0). The next day, mice were injected with 0.1 mg control IgG or UMCD6. C: Tumor growth, measured by IVIS, showed a robust decrease in bioluminescence signal in mice treated with UMCD6 compared to IgG and control (not administered PBMCs nor antibodies). The effect of UMCD6 on tumor volume can be seen from day 7 after UMCD6 administration (**p < 0.01) and was maintained until mice were euthanized (**p < 0.01). Data represents mean of 4–8 animals ± SD. D: Survival was significantly prolonged in the UMCD6 group compared to the IgG and control groups (***p < 0.001).